These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31571444)

  • 1. INSIGHTS (INSITES) on DPP 4 Inhibitors (Gliptins) for Diabetes Management in India.
    Tiwaskar M
    J Assoc Physicians India; 2019 Oct; 67(10):11-12. PubMed ID: 31571444
    [No Abstract]   [Full Text] [Related]  

  • 2. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
    Ahmed HA; May DW; Fagan SC; Segar L
    Pharmacotherapy; 2015 Mar; 35(3):277-97. PubMed ID: 25754657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of gliptins in 2011.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):81-99. PubMed ID: 22149369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer.
    Almagthali AG; Alkhaldi EH; Alzahrani AS; Alghamdi AK; Alghamdi WY; Kabel AM
    Diabetes Metab Syndr; 2019; 13(1):36-39. PubMed ID: 30641726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
    Nauck MA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
    [No Abstract]   [Full Text] [Related]  

  • 7. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.
    Kushwaha RN; Haq W; Katti SB
    Curr Med Chem; 2014; 21(35):4013-45. PubMed ID: 25245373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of type 2 diabetes mellitus in chronic kidney disease.
    Maffioli P; Derosa G
    Curr Med Res Opin; 2015 Jan; 31(1):95-7. PubMed ID: 25325220
    [No Abstract]   [Full Text] [Related]  

  • 11. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
    Turdu G; Gao H; Jiang Y; Kabas M
    Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
    Zhao Y; Yang L; Zhou Z
    J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DPP-4 inhibitors, GLP-1 receptor agonists].
    Hamasaki A; Inagaki N
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():654-61. PubMed ID: 21766677
    [No Abstract]   [Full Text] [Related]  

  • 14. DPP IV inhibitors: successes, failures and future prospects.
    Kshirsagar AD; Aggarwal AS; Harle UN; Deshpande AD
    Diabetes Metab Syndr; 2011; 5(2):105-12. PubMed ID: 22813415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
    Sehra D; Sehra S
    J Assoc Physicians India; 2011 Nov; 59():744; author reply 744. PubMed ID: 22616349
    [No Abstract]   [Full Text] [Related]  

  • 16. Who would really benefit from DPP-4 inhibitors?
    Mikhail N
    Endocrine; 2014 May; 46(1):6-7. PubMed ID: 24510631
    [No Abstract]   [Full Text] [Related]  

  • 17. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials.
    Packer M
    Am J Med; 2018 Jul; 131(7):e287-e289. PubMed ID: 29307538
    [No Abstract]   [Full Text] [Related]  

  • 19. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 20. Gliptins: a new class of oral hypoglycaemic agent.
    Chahal H; Chowdhury TA
    QJM; 2007 Nov; 100(11):671-7. PubMed ID: 17881415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.